ZA200509026B - Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts - Google Patents
Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts Download PDFInfo
- Publication number
- ZA200509026B ZA200509026B ZA200509026A ZA200509026A ZA200509026B ZA 200509026 B ZA200509026 B ZA 200509026B ZA 200509026 A ZA200509026 A ZA 200509026A ZA 200509026 A ZA200509026 A ZA 200509026A ZA 200509026 B ZA200509026 B ZA 200509026B
- Authority
- ZA
- South Africa
- Prior art keywords
- water
- carrier
- pharmaceutical preparation
- active ingredient
- edta
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 19
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 title claims abstract description 6
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title claims abstract description 6
- 229950008325 levothyroxine Drugs 0.000 title claims abstract description 6
- 239000007787 solid Substances 0.000 title claims abstract description 6
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 title claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 67
- 230000000694 effects Effects 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 229940035722 triiodothyronine Drugs 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 35
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000000536 complexating effect Effects 0.000 claims description 5
- -1 e.g. Substances 0.000 claims description 5
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000011734 sodium Substances 0.000 description 30
- 239000003826 tablet Substances 0.000 description 30
- 238000001035 drying Methods 0.000 description 12
- 239000000080 wetting agent Substances 0.000 description 8
- 229960004106 citric acid Drugs 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 150000004686 pentahydrates Chemical class 0.000 description 4
- 229940036555 thyroid hormone Drugs 0.000 description 4
- 239000005495 thyroid hormone Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- SBXXSUDPJJJJLC-YDALLXLXSA-M liothyronine sodium Chemical class [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 SBXXSUDPJJJJLC-YDALLXLXSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- JMHCCAYJTTWMCX-QWPJCUCISA-M sodium;(2s)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;pentahydrate Chemical class O.O.O.O.O.[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 JMHCCAYJTTWMCX-QWPJCUCISA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT6672003 | 2003-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200509026B true ZA200509026B (en) | 2007-03-28 |
Family
ID=33314944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200509026A ZA200509026B (en) | 2003-05-02 | 2005-11-08 | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1622587B1 (pt) |
| JP (1) | JP5414146B2 (pt) |
| AT (1) | ATE465718T1 (pt) |
| AU (1) | AU2004234176B2 (pt) |
| BR (1) | BRPI0410021A (pt) |
| CA (1) | CA2523079C (pt) |
| DE (1) | DE502004011103D1 (pt) |
| DK (1) | DK1622587T3 (pt) |
| ES (1) | ES2344294T3 (pt) |
| PT (1) | PT1622587E (pt) |
| RU (1) | RU2361573C2 (pt) |
| WO (1) | WO2004096177A1 (pt) |
| ZA (1) | ZA200509026B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
| FR2897267A1 (fr) * | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
| US20100119601A1 (en) * | 2007-04-11 | 2010-05-13 | Pharmaceutical Productions Inc. | Melatonin tablet and methods of preparation and use |
| PE20150597A1 (es) * | 2012-08-20 | 2015-05-06 | Merck Patent Gmbh | Preparacion farmaceutica solida que contiene levotiroxina |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225204A (en) * | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
| DE19541128C2 (de) * | 1995-10-27 | 1997-11-27 | Henning Berlin Gmbh & Co | Stabilisierte schilddrüsenhormonhaltige Arzneimittel |
| US5635209A (en) * | 1995-10-31 | 1997-06-03 | Vintage Pharmaceuticals, Inc. | Stabilized composition of levothyroxine sodium medication and method for its production |
| EP0861073B1 (en) * | 1995-11-14 | 2004-07-28 | Abbott GmbH & Co. KG | Stabilized thyroid hormone preparations and methods of making same |
| JP2001114712A (ja) * | 1996-04-16 | 2001-04-24 | Takeda Chem Ind Ltd | Ｄ−マンニトールおよびその製造法 |
| DE19653410A1 (de) * | 1996-12-20 | 1998-06-25 | Basf Ag | Verwendung von Carotinoid-Solubilisaten zum Färben von Lebensmitteln und pharmazeutischen Zubereitungen |
| JP2001516365A (ja) * | 1997-11-17 | 2001-09-25 | ギスト ブロカデス ベスローテン フェンノートシャップ | クラブラネート及び１種以上の賦形剤を含む顆粒 |
| JP3274416B2 (ja) * | 1998-05-29 | 2002-04-15 | 佐藤製薬株式会社 | 口腔内崩壊性粒状製剤 |
| FR2781793B1 (fr) | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
| JP2000060535A (ja) * | 1998-08-21 | 2000-02-29 | Kyowa Hakko Kogyo Co Ltd | 微生物菌体の保存方法 |
| JP3491887B2 (ja) * | 1999-04-28 | 2004-01-26 | フロイント産業株式会社 | 糖アルコール造粒物集合体の製法 |
| GB9919487D0 (en) * | 1999-08-17 | 1999-10-20 | Nestle Sa | Moulded onfectionery product comprising vegetables |
| JP4677084B2 (ja) * | 1999-09-30 | 2011-04-27 | 武田薬品工業株式会社 | 塩酸ブロムヘキシンを含有する固形製剤 |
| US6399101B1 (en) * | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
| CN1211382C (zh) * | 2000-06-30 | 2005-07-20 | 葛兰素集团有限公司 | 喹唑啉二甲苯磺酸盐化合物 |
| ES2174734B1 (es) * | 2000-11-03 | 2003-10-01 | Belmac S A Lab | Nueva formulacion galenica de paracetamol dispersable y soluble, procedimiento para su preparacion y aplicaciones. |
| BR0207297A (pt) * | 2001-02-15 | 2005-04-19 | King Pharmaceuticals Inc | Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo |
| JP4291962B2 (ja) * | 2001-03-27 | 2009-07-08 | あすか製薬株式会社 | 安定な甲状腺ホルモン含有固形製剤組成物 |
| PL369972A1 (en) | 2002-01-07 | 2005-05-02 | Abbott Gmbh & Co.Kg | Crystallization of amino acids using ultrasonic agitation |
-
2004
- 2004-05-03 AT AT04730797T patent/ATE465718T1/de active
- 2004-05-03 JP JP2006503952A patent/JP5414146B2/ja not_active Expired - Lifetime
- 2004-05-03 EP EP04730797A patent/EP1622587B1/de not_active Revoked
- 2004-05-03 WO PCT/AT2004/000150 patent/WO2004096177A1/de active Search and Examination
- 2004-05-03 CA CA2523079A patent/CA2523079C/en not_active Expired - Lifetime
- 2004-05-03 RU RU2005137577/15A patent/RU2361573C2/ru active
- 2004-05-03 AU AU2004234176A patent/AU2004234176B2/en not_active Ceased
- 2004-05-03 DE DE502004011103T patent/DE502004011103D1/de not_active Expired - Lifetime
- 2004-05-03 ES ES04730797T patent/ES2344294T3/es not_active Expired - Lifetime
- 2004-05-03 BR BRPI0410021-2A patent/BRPI0410021A/pt not_active Application Discontinuation
- 2004-05-03 DK DK04730797.0T patent/DK1622587T3/da active
- 2004-05-03 PT PT04730797T patent/PT1622587E/pt unknown
-
2005
- 2005-11-08 ZA ZA200509026A patent/ZA200509026B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005137577A (ru) | 2006-05-10 |
| CA2523079A1 (en) | 2004-11-11 |
| CA2523079C (en) | 2012-08-14 |
| RU2361573C2 (ru) | 2009-07-20 |
| EP1622587B1 (de) | 2010-04-28 |
| PT1622587E (pt) | 2010-07-07 |
| JP5414146B2 (ja) | 2014-02-12 |
| JP2006525234A (ja) | 2006-11-09 |
| BRPI0410021A (pt) | 2006-04-25 |
| ES2344294T3 (es) | 2010-08-24 |
| DK1622587T3 (da) | 2010-08-23 |
| EP1622587A1 (de) | 2006-02-08 |
| WO2004096177A1 (de) | 2004-11-11 |
| AU2004234176B2 (en) | 2010-05-13 |
| DE502004011103D1 (de) | 2010-06-10 |
| AU2004234176A1 (en) | 2004-11-11 |
| ATE465718T1 (de) | 2010-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1338889C (en) | Morphine containing composition | |
| US5635209A (en) | Stabilized composition of levothyroxine sodium medication and method for its production | |
| US5348745A (en) | Aqueous granulation solution and a method of tablet granulation | |
| UA29513C2 (uk) | Фармацевтична композиція, що включає (е)-3,5-дигідрокси-7-[4'-4''-фторфеніл-2'-циклопропілхінолін-3'-іл]-6- гептенову кислоту | |
| EA006553B1 (ru) | Твердые фармацевтические композиции, содержащие 4-амино-3-замещенные производные бутановой кислоты, способ их получения и применение увлажнителя для их стабилизации | |
| JPH11514629A (ja) | 安定な甲状腺ホルモン含有薬剤 | |
| ZA200509026B (en) | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts | |
| FR2802424A1 (fr) | Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale | |
| US8293272B2 (en) | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts | |
| UA73474C2 (uk) | Фармацевтична композиція у вигляді таблетки, яка містить левотироксин натрію, та спосіб її одержання | |
| ES2234051T3 (es) | Composiciones farmaceuticas de cilansetron estabilizadas contra la racemizacion. | |
| JP2007145758A (ja) | 安定化された医薬製剤 | |
| JP5516401B2 (ja) | 固形内服製剤 | |
| US4067974A (en) | Stabilized solid form choline salicylate compositions | |
| JP2809971B2 (ja) | 血液透析用製剤 | |
| US20110038934A1 (en) | Pharmaceutical composition with atorvastatin active ingredient | |
| GB1575977A (en) | Solid choline salicylate compositions | |
| KR920008161B1 (ko) | 오메프라졸 경구용 약제의 제조방법 | |
| JPH0242811B2 (pt) | ||
| RU2655307C1 (ru) | Фармацевтическая композиция для профилактики и лечения заболеваний щитовидной железы | |
| RU2188019C1 (ru) | Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения | |
| JPH08193027A (ja) | 昇華イブプロフェンの再結晶防止方法 | |
| IE45201B1 (en) | Solid choline salicylate compositions | |
| JP2003095939A (ja) | 安定なプラバスタチンナトリウム錠 | |
| JPH02311419A (ja) | 血液透析用製剤およびその製造方法 |